This is a working overview of reverse-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
| Property | Value | Notes |
|---|---|---|
| Molecular mass | Approximately 3.4 to 3.6 kDa | Depends on whether the affinity complex is attached |
| Appearance | White to off-white lyophilized powder | Freeze-dried solid, often in a sealed vial |
| Solubility | Soluble in water and aqueous buffers | Dissolution rate varies with pH and buffer salt |
| Typical storage | Below minus 20 degrees Celsius, dry and dark | Dissolved material is usually kept cold and used promptly |
| Common analytical methods | Reversed-phase HPLC and mass spectrometry | Peptide mapping and amino acid analysis add sequence detail |
Reverse-phase high-performance liquid chromatography is the standard tool for purity assessment. The technique separates the target peptide from truncated or modified byproducts. Mass spectrometry confirms molecular weight and supports sequence verification. Electrospray ionization and matrix-assisted laser desorption are both used. Amino acid analysis provides an independent check on composition. Purity values are commonly reported as area percentage from the chromatogram. Residual trifluoroacetate and water content are also measured in many quality programs.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
== External links == Bak Sangmee, From Strange Bitter Concoction to Romantic Necessity: The Social History of Coffee Drinking in South Korea. (Korea Journal Vol.45. No.2 Summer, 2005 pp. 37~59) Korea Coffee Market, Terarosa Coffee, Yunson, Lee Korea's coffee culture, korea.net Episode #33: The History of Coffee in Korea, KBS World The History of Coffee in Korea, Daniel Gray Korean Coffee Culture 101 – History & Timeline Archived 2016-12-06 at the Wayback Machine Café Culture in Seoul, Korea JungHee Jang, Korean Café Culture: What Korean Cafés Mean to Koreans Cultural Meaning and Power of Starbucks in South Korea
===== MeSH D08.811.277.040 – acid anhydride hydrolases (EC 3.6) ===== MeSH D08.811.277.040.025 – adenosinetriphosphatase MeSH D08.811.277.040.025.095 – ca(2+) mg(2+)-atpase MeSH D08.811.277.040.025.125 – ca(2+)-transporting atpase MeSH D08.811.277.040.025.150 – dynein atpase MeSH D08.811.277.040.025.237 – muts dna mismatch-binding protein MeSH D08.811.277.040.025.281 – muts homolog 2 protein MeSH D08.811.277.040.025.303 – n-ethylmaleimide-sensitive proteins MeSH D08.811.277.040.025.325 – proton-translocating atpases MeSH D08.811.277.040.025.325.249 – bacterial proton-translocating atpases MeSH D08.811.277.040.025.325.500 – chloroplast proton-translocating atpases MeSH D08.811.277.040.025.325.625 – h(+)-k(+)-exchanging atpase MeSH D08.811.277.040.025.325.750 – mitochondrial proton-translocating atpases MeSH D08.811.277.040.025.325.875 – vacuolar proton-translocating atpases MeSH D08.811.277.040.025.450 – kinesin MeSH D08.811.277.040.025.525 – myosins MeSH D08.811.277.040.025.525.500 – myosin type i MeSH D08.811.277.040.025.525.750 – myosin type ii MeSH D08.811.277.040.025.525.750.124 – cardiac myosins MeSH D08.811.277.040.025.525.750.124.249 – atrial myosins MeSH D08.811.277.040.025.525.750.124.500 – ventricular myosins MeSH D08.811.277.040.025.525.750.374 – nonmuscle myosin type iia MeSH D08.811.277.040.025.525.750.500 – nonmuscle myosin type iib MeSH D08.811.277.040.025.525.750.750 – skeletal muscle myosins MeSH D08.811.277.040.025.525.750.875 – smooth muscle myosins MeSH D08.811.277.040.025.525.812 – myosin type iii MeSH D08.811.277.040.025.525.843 – myosin type iv MeSH D08.811.277.040.025.525.875 – myosin type v MeSH D08.811.277.040.025.600 – na(+)-k(+)-exchanging atpase MeSH D08.811.277.040.050 – apyrase MeSH D08.811.277.040.330 – gtp phosphohydrolases MeSH D08.811.277.040.330.200 – dynamins MeSH D08.811.277.040.330.200.100 – dynamin i MeSH D08.811.277.040.330.200.200 – dynamin ii MeSH D08.811.277.040.330.200.300 – dynamin iii MeSH D08.811.277.040.330.300 – gtp-binding proteins MeSH D08.811.277.040.330.300.100 – gtp phosphohydrolase-linked elongation factors MeSH D08.811.277.040.330.300.100.200 – peptide elongation factor g MeSH D08.811.277.040.330.300.100.700 – peptide elongation factor tu MeSH D08.811.277.040.330.300.100.800 – peptide elongation factor 1 MeSH D08.811.277.040.330.300.100.850 – peptide elongation factor 2 MeSH D08.811.277.040.330.300.200 – heterotrimeric gtp-binding proteins MeSH D08.811.277.040.330.300.200.100 – gtp-binding protein alpha subunits MeSH D08.811.277.040.330.300.200.100.100 – gtp-binding protein alpha subunits, g12-g13 MeSH D08.811.277.040.330.300.200.100.200 – gtp-binding protein alpha subunits, gi-go MeSH D08.811.277.040.330.300.200.100.200.500 – gtp-binding protein alpha subunit, gi2 MeSH D08.811.277.040.330.300.200.100.300 – gtp-binding protein alpha subunits, gq-g11 MeSH D08.811.277.040.330.300.200.100.400 – gtp-binding protein alpha subunits, gs MeSH D08.811.277.040.330.300.200.800 – transducin MeSH D08.811.277.040.330.300.400 – monomeric gtp-binding proteins MeSH D08.811.277.040.330.300.400.100 – adp-ribosylation factors MeSH D08.811.277.040.330.300.400.100.100 – ADP-ribosylation factor 1 MeSH D08.811.277.040.330.300.400.400 – rab gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.025 – rab1 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.050 – rab2 gtp-binding protein MeSH D08.811.277.040.330.300.400.400.100 – rab3 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.100.500 – rab3a gtp-binding protein MeSH D08.811.277.040.330.300.400.400.150 – rab4 gtp-binding proteins MeSH D08.811.277.040.330.300.400.400.200 – rab5 gtp-binding proteins MeSH D08.811.277.040.330.300.400.450 – ral gtp-binding proteins MeSH D08.811.277.040.330.300.400.462 – ran gtp-binding protein MeSH D08.811.277.040.330.300.400.475 – rap gtp-binding proteins MeSH D08.811.277.040.330.300.400.475.100 – rap1 gtp-binding proteins MeSH D08.811.277.040.330.300.400.500 – ras proteins MeSH D08.811.277.040.330.300.400.500.300 – oncogene protein p21(ras) MeSH D08.811.277.040.330.300.400.500.600 – proto-oncogene proteins p21(ras) MeSH D08.811.277.040.330.300.400.700 – rho gtp-binding proteins MeSH D08.811.277.040.330.300.400.700.050 – cdc42 gtp-binding protein MeSH D08.811.277.040.330.300.400.700.060 – cdc42 gtp-binding protein, saccharomyces cerevisiae MeSH D08.811.277.040.330.300.400.700.100 – rac gtp-binding proteins MeSH D08.811.277.040.330.300.400.700.100.500 – rac1 gtp-binding protein MeSH D08.811.277.040.330.300.400.700.200 – rhoa gtp-binding protein MeSH D08.811.277.040.330.300.400.700.300 – rhob gtp-binding protein MeSH D08.811.277.040.465 – nucleoside-triphosphatase MeSH D08.811.277.040.600 – pyrophosphatases MeSH D08.811.277.040.600.399 – inorganic pyrophosphatase MeSH D08.811.277.040.600.800 – thiamine pyrophosphatase MeSH D08.811.277.040.850 – thiamin-triphosphatase
=== The Commander === "The Commander" (Jack Farthing) is ostensibly an old friend of Henry's who shows up at his 40th birthday while an intoxicated Henry makes a scene before dinner guests. The Commander takes Henry to a pub where Henry spots his housekeeper Molly and her friend George; after George makes insulting comments about Yasmin, Henry viciously beats him at the Commander's provocation. The Commander is revealed to be Henry's hallucination of his late father, whose suicide on his own 40th birthday was witnessed by Henry as a child. Henry himself nearly attempts suicide the following morning in his father's vintage Jaguar E-Type via carbon monoxide poisoning, but relents at the last moment.
Sources: en.wikipedia.org
=== Conservation of mass in mixing calculations === 2H and 1H are stable isotopes. Therefore, the 2H/1H ratio of a pool containing hydrogen, remains constant as long as no hydrogen is added or removed, a property known as conservation of mass. When two pools of hydrogen A and B mix with molar amounts of hydrogen mA and mB, each with their own starting fractional abundance of deuterium (FA and FB), then the fractional abundance of the resulting mixture is given by the following exact equation:
In the final years of his reign, Spain suffered a financial recession that led to a political crisis, which also affected Juan Carlos's popularity and was a key factor in his decision to abdicate in 2014.
A medical test is a medical procedure performed to detect, diagnose, or monitor diseases, disease processes, susceptibility, or to determine a course of treatment. The tests are classified by speciality field, conveying in which ward of a hospital or by which specialist doctor these tests are usually performed. The ICD-10-CM is generally the most widely used standard by insurance companies and hospitals who have to communicate with one another, for giving an overview of medical tests and procedures. It has over 70,000 codes. This list is not exhaustive but might be useful as a guide, even though it is not yet categorized consistently and only partly sortable.
=== Pharmacokinetics === Octreotide is absorbed quickly and completely after subcutaneous application. Maximal plasma concentration is reached after 30 minutes. The elimination half-life is 100 minutes (1.7 hours) on average when applied subcutaneously; after intravenous injection, the substance is eliminated in two phases with half-lives of 10 and 90 minutes, respectively.
Sources: en.wikipedia.org
The version carrying the affinity complex bears a maleimide group that binds serum albumin, which extends its circulation time to several days. The version without it lacks this group and clears within roughly half an hour. The two are chemically related but behave very differently once in the body.
In common usage the name without the affinity complex is often equated with MOD GRF 1-29, a fragment carrying four stabilizing substitutions. Strictly speaking, the term originally referred to the albumin-binding version. The overlap in naming causes frequent ambiguity in both informal and technical writing.
Reversed-phase chromatography separates the peptide from related impurities and yields a purity estimate. Mass spectrometry confirms the molecular mass and detects modifications such as oxidation. Sequence-level checks rely on peptide mapping or amino acid analysis when stronger confirmation is needed.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.